AEGiS-AIDSWeekly: HIV/AIDS Co-Infection: HIV is a 'double hit' to the brain

Important note: Information in this article was accurate in August 2007. The state of the art may have changed since the publication date.

HIV/AIDS Co-Infection: HIV is a 'double hit' to the brain

AIDSWEEKLY Plus; Monday, August 27, 2007
Staff Medical Writers

NewsRx -- New evidence reported in Cell Stem Cell, a publication of Cell Press, offers a novel perspective on how the HIV/AIDS virus leads to learning and memory deficits, a condition known as HIV-associated dementia. A protein found on the surface of the virus not only kills some mature brain cells, as earlier studies had shown, but it also prevents the birth of new brain cells by crippling “adult neural progenitors,” the new study finds. Those progenitor cells are the closest thing to stem cells that have been found in the adult brain.

By elucidating the mechanism responsible for the neurodegeneration and dementia seen in people infected with HIV, the findings made in mice that produce the damaging HIV protein may open the door to new therapies, according to the researchers.

“The breakthrough here is that the AIDS virus prevents stem cells in the brain from dividing; it hangs them up,” said Stuart Lipton of the Burnham Institute for Medical Research and the University of California at San Diego. “It’s the first time that the virus has ever been shown to affect stem cells.”

“It’s a double hit to the brain,” added collaborator Marcus Kaul, who is also of the Burnham Institute and UCSD. “The HIV protein both causes brain injury and prevents its repair.”

Physicians first recognized that HIV infection could lead to a profound form of dementia—most commonly in those with an advanced stage of the disease—early on. The success of antiretroviral therapies in keeping the “viral load” down has helped to reduce the severity of the dementia in recent years. Nonetheless, the prevalence is rising as HIV-infected people are living longer. The anti-HIV drugs don’t infiltrate the brain well, allowing for a “secret reservoir” of virus, Lipton explained. Such persistent exposure of the central nervous system to HIV is a major risk factor for the development of HIV-associated dementia.

Lipton’s team previously discovered that the brain deficits could be triggered by gp120—the viral coat protein that latches onto human cells—even in the absence of any viral infection. They also showed that the protein disrupts a key cell-cycle pathway (including p38 mitogen-activated protein kinase or MAPK), leading to the death of certain mature neurons.

The researchers now find that gp120 in mice also slows the production of new neurons in the hippocampus, a brain region central to learning and memory. Newborn neurons become integrated into existing brain circuits and are thought to contribute to certain forms of learning and memory, they said.

Moreover, they found that it is the same MAPK pathway earlier linked to the death of mature neurons that lies at the root of the progenitor cells’ dysfunction. That a similar enzyme is involved in both brain-damaging effects is simply “serendipitous,” according to the researchers.

“Knowing the mechanism, we can start to approach this therapeutically,” Lipton said. “This indicates that we might eventually treat this form of dementia by either ramping up brain repair or protecting the repair mechanism,” Kaul added.

Keywords: HIV/AIDS Co-Infection, AIDS, Acquired Immunodeficiency Syndrome, Biotechnology, Central Nervous System Disease, Dementia, Drug Development, HIV, Human Immunodeficiency Virus Neurological Disorder, Stem Cell Research, Therapy, Treatment, Viral, Virology, Burnham Institute for Medical Research.

This article was prepared by AIDS Weekly editors from staff and other reports.

2007-08-27
AW070810

Copyright © 2007 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone/Firestone Charitable Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright © 1980,2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.